May 15, 2020 / 7:14 PM / 2 months ago

U.S. FDA approves Bristol Myers' combo therapy for lung cancer

May 15 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co’s therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck’s Keytruda.

The combination of Bristol's treatments, Opdivo and Yervoy, is approved for treating patients with non-small cell lung cancer, the FDA said here (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila and Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below